- Home
- LCTX vs SOL Comparison
LCTX vs SOL Comparison
Compare LCTX & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- SOL
- Stock Information
- Founded
- LCTX 1990
- SOL 2005
- Country
- LCTX United States
- SOL United States
- Employees
- LCTX N/A
- SOL N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- SOL Semiconductors
- Sector
- LCTX Health Care
- SOL Technology
- Exchange
- LCTX Nasdaq
- SOL Nasdaq
- Market Cap
- LCTX 95.2M
- SOL 84.6M
- IPO Year
- LCTX N/A
- SOL 2008
- Fundamental
- Price
- LCTX $0.49
- SOL $1.57
- Analyst Decision
- LCTX Strong Buy
- SOL Buy
- Analyst Count
- LCTX 5
- SOL 3
- Target Price
- LCTX $4.20
- SOL $3.50
- AVG Volume (30 Days)
- LCTX 860.2K
- SOL 105.7K
- Earning Date
- LCTX 05-13-2025
- SOL 05-27-2025
- Dividend Yield
- LCTX N/A
- SOL N/A
- EPS Growth
- LCTX N/A
- SOL N/A
- EPS
- LCTX N/A
- SOL N/A
- Revenue
- LCTX $9,557,000.00
- SOL $85,621,000.00
- Revenue This Year
- LCTX N/A
- SOL N/A
- Revenue Next Year
- LCTX $232.66
- SOL $45.37
- P/E Ratio
- LCTX N/A
- SOL N/A
- Revenue Growth
- LCTX 19.42
- SOL N/A
- 52 Week Low
- LCTX $0.37
- SOL $1.04
- 52 Week High
- LCTX $1.40
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- LCTX 54.19
- SOL 60.48
- Support Level
- LCTX $0.45
- SOL $1.50
- Resistance Level
- LCTX $0.49
- SOL $1.40
- Average True Range (ATR)
- LCTX 0.03
- SOL 0.07
- MACD
- LCTX 0.00
- SOL 0.03
- Stochastic Oscillator
- LCTX 72.25
- SOL 85.29
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.